Sign In
Buy ASND
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of “Moderate Buy” from Brokerages
02:10am, Tuesday, 10'th Mar 2026
Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eighteen ratings firms that are covering the company, Marketbeat.com reports. One investme
Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript
02:42pm, Wednesday, 04'th Mar 2026
Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Ascendis Pharma: Yuviwel Approved Despite Legal Challenges
12:05pm, Tuesday, 03'rd Mar 2026
Ascendis Pharma secured FDA approval for Yuviwel in achondroplasia, despite ongoing legal challenges from BioMarin. I expect Yuviwel's U.S. sales to be modest, with stronger international growth poten
American Century Companies Inc. Buys 13,797 Shares of Ascendis Pharma A/S $ASND
03:06am, Tuesday, 03'rd Mar 2026
American Century Companies Inc. lifted its stake in shares of Ascendis Pharma A/S (NASDAQ: ASND) by 2.6% during the third quarter, according to its most recent filing with the Securities and Exchange
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript
04:57pm, Monday, 02'nd Mar 2026
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
08:43am, Monday, 02'nd Mar 2026
COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annu
Ascendis Wins FDA Approval For Rare Disease Therapy
08:02am, Monday, 02'nd Mar 2026
Ascendis Pharma shares rise after FDA approves Yuviwel, a weekly treatment for children with achondroplasia.
Ascendis wins U.S. approval for therapy for children with dwarfism
06:04pm, Friday, 27'th Feb 2026
The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy for children with a rare genetic disorder that causes dwarfism, the company said.
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
05:57pm, Friday, 27'th Feb 2026
COPENHAGEN, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has granted approval under the FDA's Accelerate
Artisan Partners Limited Partnership Has $739.75 Million Stock Position in Ascendis Pharma A/S $ASND
03:16am, Friday, 27'th Feb 2026
Artisan Partners Limited Partnership lowered its position in Ascendis Pharma A/S (NASDAQ: ASND) by 6.8% during the third quarter, according to its most recent Form 13F filing with the Securities and E
Ascendis Pharma FY 2025 Results: More Than A Takeover Story
07:33am, Thursday, 12'th Feb 2026
Ascendis Pharma has transitioned into a revenue-scaled commercial biotech, driven by Yorvipath's rapid adoption and strong FY25 results. ASND's 2025 product revenue surged to €684 million, with Yorv
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
08:24pm, Wednesday, 11'th Feb 2026
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
04:01pm, Wednesday, 11'th Feb 2026
COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
04:01pm, Wednesday, 04'th Feb 2026
COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday
HARBOR CAPITAL ADVISORS, INC. Sells 269 Shares of Ascendis Pharma AS (ASND)
01:52pm, Tuesday, 20'th Jan 2026
Summary HARBOR CAPITAL ADVISORS, INC. reduced its stake in Ascendis Pharma AS (ASND) by 1.17%, selling 269 shares and holding 22,734 shares valued at a
